Teaching hospital

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

Retrieved on: 
tisdag, maj 7, 2024
Science, Muscle & Nerve, Survival, Euronext, Doctor of Philosophy, Patient, ALS, Physician, Neurology, Teaching hospital, Health, Medical school, Philosophy, Pharmaceutical industry

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine.
  • The article, entitled ‘Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice’, is accessible online from the Muscle & Nerve website ( https://onlinelibrary.wiley.com/doi/epdf/10.1002/mus.28101 ) [1].
  • Furthermore, because post-onset ΔFS is derived from information routinely collected as part of standard patient care and monitoring, it provides a suitable patient selection tool for treating physicians.
  • The use of post-onset ΔFS patient categorization allows for innovative ALS trial design that may facilitate optimization of drug effectiveness and patient management.

ICPO Foundation awards ICPO Academy stipends to the Department of Nuclear Medicine at Osaka University Hospital

Retrieved on: 
måndag, maj 6, 2024
Pillar, PET-CT, Nuclear medicine, Research, Clinic, Curriculum, Medical physics, Nursing, Osaka University Hospital, Principal, ICPO, FAPI, Radiochemistry, Osaka University, Teaching hospital, Thyroid cancer, Health, Associate, Acid test (gold)

Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.

Key Points: 
  • Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.
  • ICPO offers industry-funded stipends for the ICPO Academy for Theranostics to dedicated healthcare professionals worldwide.
  • "Through this agreement, we have the opportunity to provide advanced training in theranostics to team members of the Department for Nuclear Medicine at Osaka University Hospital.
  • Osaka University Hospital, known for its dedication to excellence, places significant emphasis on research and development in the medical field.

Nimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology

Retrieved on: 
tisdag, maj 7, 2024
Biometrics, Health, Pharmaceutical, Clinical Trials, Oncology, University, Trillium, Nimbus, Drug, Trial of the century, Growth, WRN, Pfizer, GSK, Patient, University Hospital of Zürich, Harvard Medical School, Teaching hospital, HPK1, Therapy, Werner syndrome helicase, Biotechnology, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology.
  • “We are delighted to welcome Anita to the executive team as we enter a new stage of growth at Nimbus with plans to further expand our focus in oncology,” said Nathalie Franchimont, M.D., Ph.D, Chief Medical Officer at Nimbus.
  • Most recently, she provided strategic consulting to biotechnology companies, developing clinical development strategies for multiple early-stage oncology assets.
  • Previously, she served as Vice President and Head of Clinical Development, Oncology at Trillium Therapeutics (acquired by Pfizer in 2021).

The Ricco Dental Group Announces Its New Doctor and Massapequa, NY, Location

Retrieved on: 
onsdag, maj 8, 2024
Consumer, Funding of science, University, Dental care, Health, State university system, State, Private practice, Dentistry, DMD, Dental implant, The Stony Brook School, Patient, North Shore University Hospital, Teaching hospital, Dentist

MASSAPEQUA, N.Y., May 8, 2024 /PRNewswire-PRWeb/ -- The Ricco Dental Group is pleased to announce that it has added a new location in Massapequa, NY. The practice offers comprehensive family dental care under Dr. Steven Ricco and Dr. Jay B. Lubliner. Visit the practice's website at https://www.thericcodentalgroup.com.

Key Points: 
  • The Ricco Dental Group is pleased to announce that it has added a new location in Massapequa, NY.
  • MASSAPEQUA, N.Y., May 8, 2024 /PRNewswire-PRWeb/ -- The Ricco Dental Group is pleased to announce that it has added a new location in Massapequa, NY.
  • The practice offers comprehensive family dental care under Dr. Steven Ricco and Dr. Jay B. Lubliner.
  • I am glad to join The Ricco Dental Group and continue serving the people of Long Island and the surrounding area.

Fresh Start Surgical Gifts Tees Up for 9th Annual Celebrity Golf Classic, Hosted by Jermaine Dye in Chicago on May 19-20

Retrieved on: 
tisdag, maj 7, 2024
Smoke, Cream, Organization, University, Rady Children's Hospital, Fresh Start, Comer Children's Hospital, Chicago White Sox, River, Hospital, Hope, Heart, VIP, Aviation, Family, Golf, Farm, Teaching hospital, Rich Harvest Farms, Lexus, Anatomical pathology, Isaia, Rivers Casino, Health

CHICAGO, May 7, 2024 /PRNewswire/ -- Nationally recognized nonprofit, Fresh Start Surgical Gifts , is gearing up for an incredible golf event on the course during its 9th Annual Celebrity Golf Classic, hosted by athlete and longtime supporter Jermaine Dye.

Key Points: 
  • CHICAGO, May 7, 2024 /PRNewswire/ -- Nationally recognized nonprofit, Fresh Start Surgical Gifts , is gearing up for an incredible golf event on the course during its 9th Annual Celebrity Golf Classic, hosted by athlete and longtime supporter Jermaine Dye.
  • It's an honor to host this event for the ninth year," says Jermaine Dye.
  • Then on Monday, the golf tournament begins on the stunning course at Rich Harvest Farms with VIP celebrities, hosted by White Sox MVP, Jermaine Dye.
  • "We're so proud to announce the return of our 9th Annual Celebrity Golf Classic to the heart of Chicago!

EQS-News: Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries

Retrieved on: 
fredag, maj 3, 2024
FDA, Cancer, Prostate, Cell, Risk, Blood, Filter, CE marking, Cytokine, Trauma, Immunosuppression, Intensive care medicine, MD, Carcinoma, PILOT, Pain management, Patient, Lung, Teaching hospital, Clinical trial, IBS, Medical imaging

Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.

Key Points: 
  • Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
  • Following these positive results, Company has initiated process to receive CE Mark in Europe and FDA conformity in the US.
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
  • CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from the blood of cancer patients.

EQS-News: Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

Retrieved on: 
fredag, maj 3, 2024
Cancer, Safety, Blood, Immunosuppression, Intensive care medicine, Pain management, Patient, Teaching hospital, Lymphocyte, IBS, Medical device

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
  • The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
  • CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
  • Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Retrieved on: 
onsdag, april 24, 2024
Nephrology, Kidney disease, Kidney, Div, Proteinuria, European Commission, Kidney failure, CHMP, Irbesartan, Immunoglobulin A, European, EGFR, Patient, CSL Vifor, CSL, Committee, Civil service commission, RAAS, Teaching hospital, Head, Therapy, CMA, SAN, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • “The approval of this innovative treatment is based on data from the only head-to-head phase 3 clinical trial in IgAN.
  • CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.
  • In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand.

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

Retrieved on: 
tisdag, april 23, 2024
Patient, Safety, Hospital, Research, Glioblastoma, Disease, Radiopharmaceutical, Teaching hospital, IIT, ITM, Nuclear medicine, Injection, Pharmaceutical industry

Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

Key Points: 
  • Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that the first patient has been dosed in an investigator-initiated trial (IIT) with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.
  • The IIT is sponsored by the University Hospital Münster, conducted in hospitals in Münster, Essen, Cologne, and Würzburg, and supported by Helmholtz Munich and ITM.
  • After glioblastoma patients receive standard treatment with surgery, radio- and chemotherapy, individual tumor cells often remain undetected in surrounding tissue and grow again leading to relapse.
  • Patients will receive their personalized calculated total doses of ITM-31 in three fractions with an interval of 4 weeks between injections.

CEO of Collective Audience, Peter Bordes, Inducted into NJ Advertising Hall of Fame

Retrieved on: 
måndag, april 22, 2024
Ecosystem, Collective, Radio, Hospital, Adtech (company), Marketing, NJ.com, Health care, Publishing, Creative, Growth, Lombardo, Burns, Teaching hospital, Creativity, Advertising, Government, Fortune 1000, Film industry

NORTH ARLINGTON, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Collective Audience, Inc. (Nasdaq: CAUD), a leading innovator of audience-based performance advertising and media solutions, announced its CEO, Peter Bordes, has been inducted into the The New Jersey Ad Club Advertising Hall of Fame in recognition of his many career achievements and their contribution to the industry.

Key Points: 
  • NORTH ARLINGTON, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Collective Audience, Inc. (Nasdaq: CAUD), a leading innovator of audience-based performance advertising and media solutions, announced its CEO, Peter Bordes, has been inducted into the The New Jersey Ad Club Advertising Hall of Fame in recognition of his many career achievements and their contribution to the industry.
  • “Congratulations to our new Hall of Fame inductees, who have demonstrated leadership, creativity, and professional integrity throughout their careers,” stated NJ Ad Club president, Christian Estrellado.
  • The cloud-based infrastructure platform was designed from the ground up as the next generation integrated digital advertising and media ecosystem.
  • Peter Bordes – Currently CEO of Collective Audience, Bordes is a lifelong entrepreneur who also founded and is a managing partner of Trajectory Ventures and Trajectory Capital.